ENTROPY NEURODYNAMICS LIMITED — AGM Information 2020

Oct 28, 2020

==> picture [596 x 80] intentionally omitted <==

29 October 2020

Dear Shareholder

2020 Annual General Meeting – Notice and Proxy Form

The Board of Exopharm Limited (“ Company ”) advises that its 2020 Annual General Meeting will be held at 11am (AEDT) on Monday, 30 November 2020 (“ AGM ”) as a virtual meeting .

In accordance with the temporary modifications to the Corporations Act 2001 (Cth) under the Corporations (Coronavirus Economic Response) Determination (No. 3) 2020, the Company is not mailing hard copies of the Notice of the AGM ( Notice of Meeting ) to Shareholders. A copy of the Notice of Meeting can be viewed and downloaded at the following link:

- https://exopharm.com/asx announcements/

Further, given the significant health concerns attributed to the COVID-19 pandemic, the Company considers that it appropriate to hold the AGM online as a virtual meeting , in a manner that is consistent with the temporary modifications to the Corporations Act 2001 (Cth) referred to above. If you wish to virtually attend the AGM (which will be broadcast as a live webinar), please pre-register in advance here:

https://us02web.zoom.us/webinar/register/WN_D9NQW6MGQ6GoxEFJW1shBA

You may vote either at the AGM via the virtual meeting platform or beforehand by proxy. Further details regarding voting by proxy are set out in the Notice of Meeting and the enclosed personalised Proxy Form. Your proxy instruction must be received not later than 48 hours before the commencement of the AGM and any Proxy Forms received later than this time will be invalid.

Given the uncertainty surrounding the COVID-19 pandemic, by the time this Notice is received by Shareholders, circumstances may have changed but this Notice is given based on circumstances as at 29 October 2020.

Accordingly, should circumstances change, the Company will make an announcement on the ASX - market announcements platform and on the Company’s website at https://exopharm.com/asx announcements/. Shareholders are urged to monitor the ASX announcements platform and the Company’s website.

For further information, please contact the Company Secretary at sinead.teague@exopharm.com.

Yours faithfully

==> picture [87 x 36] intentionally omitted <==

Sinead Teague Company Secretary Exopharm Limited

EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1 Address: Level 17, 31 Queen Street Melbourne 3000 Telephone: 03 9111 0026 Email: info@exopharm.com Web: www.exopharm.com